EMAIL THIS PAGE TO A FRIEND

Cancer discovery

SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing.


PMID 22787087

Abstract

Using a series of detailed experiments, Zhang and colleagues establish that the prostate cancer RNA chimera SLC45A3-ELK4 is generated by cis-splicing between the 2 adjacent genes and does not involve DNA rearrangements or trans-splicing. The chimera expression is induced by androgen treatment likely by overcoming the read-through block imposed by the intergenic CCCTC insulators bound by CCCTC-binding factor repressor protein. The chimeric transcript, but not wild-type ELK4, is shown to augment prostate cancer cell proliferation.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV100985
Anti-ELK4 antibody produced in rabbit, affinity isolated antibody